Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Editor-in-Chief: David D. Ho, MD
Paul A. Volberding, MD
William A. Blattner, MD
ISSN: 1525-4135
Online ISSN: 1077-9450
Frequency: 15 issues per year
Ranking: Infectious Diseases 9/57
Immunology 26/128
Impact Factor: 4.57

July 2010 Supplement, Volume 54, Supplement 1
Inclusion of Adolescents and Young Adults in Biomedical HIV Prevention Research

Guest Editors: Bill G. Kapogiannis, M.D., Monica S. Ruiz, Ph.D., MPH, Ed Handelsman, M.D. and Sonia Lee, Ph.D.

Current Supplement

 

Journal Announcement

Journal Announcement

New Focus Area: Implementation and Operational Research

JAIDS is now accepting manuscripts for a new focus area of interest: Implementation and Operational Research.   As highlighted by NIH Director, Dr. Francis Collins “Implementation science is part of [the NIH research] mission.”

In the context of HIV/AIDS with advances in HIV therapy and care, expansion of global access to treatment, care and prevention Implementation and Operational Research, while having particular relevance to global health is an important domestic focus as well.   However the lessons learned through this research discipline are particularly relevant to guiding best practices in low-resource settings as antiretroviral drug access is expanded.  Articles that encompass the translation of knowledge, practices, and technologies into clinical care of adult and pediatric patients with HIV/AIDS and their evidence-based effectiveness in “real world settings” are of particular interest. 

View the latest Instructions to Authors.

Current Issue Highlights

Select All | Hide Details
Previous Page of 2 Next
Select All
Previous Page of 2 Next
NEW! Articles on your eReader
Login




Help

Forgot Password?

Need to Activate a New Subscription?
Recently purchased a subscription? Login or Register a new account and enter your subscription ID, or Subscribe Now!

Editors' Picks

This paper describes the safety and antiviral activity of a new CCR5 inhibitor, vicraviroc. It highlights the challenge of testing new agents in patients failing previous therapy where the limited activity of the background drugs leads to a higher failure rate. On the other hand, testing a new drug as initial therapy faces the fortunate problem of the very high potency and safety of established drug combinations.

This paper considers factors predicting treatment failure of antiretrovirals in South Africa. While most of the findings were anticipated in earlier work, this study used an original case control design substantially increasing its strengths.

The long awaited National HIV/AIDS Strategy, released by the Obama Administration in July, emphasizes prevention.  Farnham et al. document the impact of prevention to date in the US.  Will there be bipartisan support to make the needed massive investment now in the NAS framework in order to achieve huge dividends in savings to the health care system in the future?

Recognition of our Reviewers